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I This knowledge-based acuv1ty is targeted for all pharmacists and is 
L
acceptable for 1.0 hour (0. 1 CEU) of continuing education credit This 
course requires completion of the program evaluation and at least a 
70 percent grade on the program assessment questions. 
CPE Universal Activity Number (UAN)' 0048-0000-11-001-H01-P 
Objectives: 
After compleoon of this program, the reader should be able to 
1. Describe the vanables that account for differences m response to 
clopldogrel therapy and which accounts for the most vanation m 
response. 
2. List the clinical effects or complications that may result from a 
decreased paoont response to clopidogrel. 
3. Explain the vanous tesong methods available to detect a va.riaoon 
that can result m decreased clopidogrel response. 
4. Describe the vanous advanrages and disadvantages of the cur-
rently available tesong met.hods. 
5. Discuss what constitutes a i:oor metabolizer and the risks associ-
ated with this phenotype 
6. Explain the pha.rmacisrs role m advocating for and providing ac-
cess to genetc tesong 
Abstract 
Clop1dogrel, the top prescnbed 3nllplatelet med1cat1on for 1nd1-
v1duals who have experienced a myocardial infarction or cerebral 
vascular accident or who have peripheral arterial disease, 1s 
administered orally as a prodrug. It relies on hepatic metabolism 
through cytochrome P450 enzy11es for conversion to its active 
form. Current research shows that allelic variation m the gene 
coding for CYP2C19 is the main factor contributing to the variability 
of response associated with clop1dogrel treatment. Through the 
promotion of geneoc testing forvanability in the CYP2C19 gene 
and competently interpreting rest results, pharmacists have the 
opportunity to use these findings to significantly impact clopidogrel 
p<escnb1ng and dosing By tailoring an 1nd1v1dual's dosing regimen 
pharmacists can maximize the efficacy of clopldogrel for a paoent 
according to his or her genotype 
Introduction 
Over the last 11 years, physicians have presc'ibed clopidogrel (Plavix0) 
to more than 100 million people. 1 Clopidogrel s commonly used to 
prevent thrombotic events in patients who have recently experienced 
a myocardial infarction (Ml) or cerebral vasculu accident (CVA) and in 
those who have established peripheral artena disease (PAD). Given 
that clop1dogrel 1s an orally administered prodrug, ltS efficacy is de-
pendent on its b1oact1vat1on via hepatic metabolism. Cytochrome P450 
enzymes, especially CYP2C 19, are essential 'or the conversion to its 
acove form.2 Consequently, any vanab1hty In CYP2C19 can significanHy 
impact the b1oact1vat1on of clopidogrel, thereby mfluencmg ltS efficacy. 
As a result, the approved Plav1x~ product labeling caunons prescnbers 
that reduced effectiveness 1s seen 1n paoents with impaired CYP2C19 
function 
Black Box Warning 
In March 2010, the United States Food and Drug Administration (FDA) 
added a black box warning to the cloptdogrel ebehng to alert health care 
professionals that the drug may be less effecove in a certain popula-
tion of pabents who are unable to convert 1t to the active form.3 The 
black box warning states. "Clopldogrel hydrog~n sulfate effectiveness 
is dependent on 1ts acovat1on to an acave met3bolite by CYP2C 19. In 
paoenrs who are CYP2C 19 poor metabOlizers, c10ptdogre1 ar recom-
mended doses forms less of that metabolrte a'ld has a smaller effect on 
platelet funcoon. Compared with normal metabol1zers, poor CYP2C 19 
metabohzers with acute coronary syndrome or undergoing percutaneous 
coronary intervention treated with clop1dogrel at recommended doses 
exhibit higher cardiovascular event rates. Tests are available to Identify 
a patient's CYP2C 19 genotype; these tests can help determine thera-
peutic strategy. Consider alternative treatmem or treatment strategies m 
CYP2C 19 poor metabolizers." By encouraging the use of genetic tests, 
pharmacists can help in identifying patients who are poor metabolizers 
of clop1dogrel, thus promoting the personaliza1ion and improved efficacy 
of clopldogrel therapy. 
Normal Clopidogrel Metabolism 
Platelet aggregation 1s a normal response to tissue inpry; adenosine 
d1phosphate (ADP) released from platelets ac:ivates neighboring plate-
lets by binding to the P2Y 12 receptor, thus promoong platelet aggrega-
tion.• The acove form of clopidogrel inhibits this platelet aggregation by 
1rrevers1bty binding the P2Y 12 receptor and 1nh1bmng the full actlVation of 
the glycoprotem llblllla adhesion recepcors on platelets (Figure 1). 
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Figure 1. BioaclivabOn of clopidogrel via CYP450 system with CYP2C19 
being the predominant activation pathway. Conversion of clop1dogrel 
to the actJve moiety results in its mechanism of action as an inhibitor of 
adenosine d1phosphate (ADP) induced platelet aggregation. 
Following absorpbon from the small intestine, clopidogrel requires 
several in vivo activation stef'.ll for conversion to its active form (Figure 
1 ).4 Some of the absorbed drug 1s excreted back into the 1ntestme via 
P-glycoprotein(P-gp)-mediated efflux pumps , thereby decreasing the 
amount of prodrug available for activation. Only about 15 percent of 
the orally administered dose of clcpidogrel is metabolized by the GYP 
system in the liver to yield the active metabolite, while the remaining 
85 percent is hydrolyzed to an inactive form by esterases in the blood 
(Figure 1).5 The CYP2C19 enzyme in the liver has been identified as 
one of the most significant enzymes in regard to clopidogrel resistance. 
Several classifications exist pertaining to an individual's genotype for 
the CYP2C 19 enzyme; to be considered a normal metabolizer, also 
referred to as an extensive metabolizer (EM), an individual must have no 
genetic d1spanties in the gene that codes for CYP2C 19 and express the 
wi ld type allele (CYP2C19'1 )4$·7•14 An intermediate metabollzer (IM) IS a 
person with one "loss of function" allele, while a poor metabolizer (PM) 
has two "loss of funct10n" alleles.6 Intermediate and poor metabolizers 
will have a decreased activity of cbpidogrel due to a decrease m the 
formation of the acbve compound.14There are five common mutations in 
the CYP2C19 gene. ·2, '3, '4, '5 and '17 .4-'~ The most common variants 
are the first four, while the CYP2C19'17 vanant 1s associated w11t1 the 
ultra-rapid metabolizer phenotype. 
Clopidogrel Resistance Due to Genetic Variants 
Three main factors have been identified that contnbute to the overall 
1eliista11ce ur cluµi<.Jugrel uisµlayetJ i11 su 111e patients; U1elie include difler-
ences in gastrointestinal (GI) absorption, platelet receptor abnormalities, 
and variations in hepatic metabolism.4 The GI absorption of clopidogrel 
is dependent on two main features the activity of GI esterases and P-gp 
efflux pumps. Polymorphisms in the genes that code for P-gp efflux 
pumps have been associated with an increase in the GI efflux of clopi-
dogrel.9 Platelet receptor abnormalities, or polymorphisms in the genes 
coding for the glycoprotein lib/Illa or the P2Y,2 receptor, can cause 
decreased metabolite binding and subsequem decreases tn platelet 
aggregation. 
The factor with the greatest impact on the resistance to clopidogrel 
1s the genetic variations in the CYP isoenzyme pathways of hepatic 
metabollsm.4The polymorphism identified to have the most significant 
impact IS that of the CYP2C 19 gene. It is estimated that 33-50 percent 
of the population has a variant form of the CYP2C 19 gene.' Full funcbon 
of this gene, associated with the w11dtype'1allele, 1s required m both 
steps of clopidogrel metabolism: fi rst for conversion of clopidogrel to 
2-oxo-clopidogrel, and then for metabolism of 2-oxo-clopidogrel to the 
active compound (Figure 1 ).2•10 Many studies have linked variations in 
CYP2C 19 to an increased risk of death or non-fatal Ml or CVA as well as 
a greater occurrence of in-stent thromboses. TRITON-TIMI 38 investiga-
tors (ClinicalTrials.gov Identifier No. NCT00097591) identified that car-
riers of the CYP2C19'2 allele had a significantly increased risk of death 
from CV events, non-fatal Ml and CVA (p=.01J and were three limes 
more likely to experience an in-stent thrombosis (P=.02). 11 The FAST-Ml 
studies linked genetic variation in the gene coding for the given enzyme, 
especially the ·2 allele, to significantly increase the nsk of death, stroke, 
Ml, revasculanzat1on and 1n-stent thrombosis. expression of any two of 
the vanants associated with loss of function, r.art1eularty the ·2. '3, '4 , or 
'5 alleles, nearly doubled the nsk of death or nonfatal Ml or stroke w1th1n 
one year (p=.045).9 The PRING Tria l demonstrated that 1f Identified, 
1nd1viduals with genotypes indicative of poor response to clopldogrel, 
particularly those expressing the '2 or '4 alleles, could experience 
an increased degree of platelet inhibition if their dosing was modified 
from what is currently considered to be the standard dose.12 The study 
showed that while wildtype carriers had better platelet inhibition two 
hours after a 600 mg loading dose compared ;o inhibition in ·2 and •4 
individuals (p=.026), individuals with the '2 and '4 alleles had greater 
inhibition than wildtype individuals with a 1,200 mg loading dose at four 
hours (P=.002). Additionally, '2 and '4 individuals responded betterthan 
w11dtype individuals with a 150 mg maintenance dose compared to the 
standard 75 mg maintenance dose (p=.042). 
By taking into account an individual's age, BMI, lipid levels and 
CYP2C 19 genotype, approximately 22 percent of !tie vanatJOn of 
clop1dogrel response can be explained.13 This leads to the conclusion 
that assessment of the CYP2C 19 genotype may prove to be a useful 
chnical tool for helping health care providers choose the most efficacious 
antiplatelel U1erapy and dOliing regimen for a given patient. 
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Non-genetic Testing 
Phenotypmg can be performed to categorize the functional aspect of a 
particular drug metabollzmg enzyme.14 This is not a genetic test. rather, 
it involves !he patient consuming a probe drug that utilizes the enzyme 
pathway of interest Measurements are made using the probe drug and 
an inactive metabolite, and these measurements are then converted into 
Cl rC1tio U1at serves i:IS U1e "rnelal.Jolic 11:1lio." Tl1is ri:ilio is use<.J Lo deter-
mine the metabolic rate that allows an individual to be characterized as 
an EM, PM or IM. These probe tests can be performed using a single 
probe, or a "cocktail" of several probe drugs can be utilized to assess 
multiple enzyme pathways concurrently. Before a "cocktail" is used, it 
must be detenmined that no drug interactions exist between any of the 
probes used to avoid confounding the resultant metabolic ratios. 
The phenotyp1c categones can be used to quantify how a patJent will 
metabolize a drug ublizing that certain enzyme.14 The effect of being a 
PM depends on whether the drug in question is pharmacologically active 
or a prodrug. In lhe case of clopidogrel, a PM will experience a decrease 
in the bioava1lab1hty of the active form of the drug. Phenotyping may be 
difficult to perform cllnically because the measurements are not taken 
until a number of hours after drug administration, therefore making th IS 
type of testing more swtable for a research setting.14 
An additional testing option is the proprietary VerifyNow-P2Y12 test, a 
point-of-care assay that was developed by Accumetrics. 15 A small blood 
sample is taken, and an ADP agonist is used to stimulate platelet aggre-
gation. The test then measures hew well platelet aggregation is impaired 
by clopidogrel. Thrombin receptoragonists are also used to approximate 
the patienrs baseline platelet aggregation.5 
Genetic Testing 
Molecular genetic testing entails examining the gene or genes that 
code for an enzyme to see which alleles are present. There are several 
generic tests available 10 investigate how well an individual will metabo-
lize clop1dogrel. Two available tests are AmpliCl1ip™, developed by 
Roche Diagnosucs, and Quest Diagnostic's AccuType™ CP. 1618 These 
two genetic tests involve taking a patient's blood sample and testing 
for variants in the CYP2C 19 genes using polymerase chain reactions 
(PCRs), which is a method to make many copies of the genes so it can 
be more easily measured. A computer program then analyzes the PCR 
data and determines the genotype and corresponding phenotype of the 
patient 16.11 
The AmpliChip™ test is designed to be able to have the results available 
in an eight-hour period.19 However, the time it takes for a patient's blood 
to be drawn and tested and the resu lts to be returned varies depend-
ing on the lab and test used. In order for these genetic tes ts to become 
more clinically useful in clopidogre l therapy, technology must be devel-
oped to make test results available prior to dosing. Research currently 
is being done on a technology that involves the use of a fluorescence-
based assay that measures an energy exchange to distinguish the 
target DNA sequence that codes for the specific enzyme.19 The goal rs to 
develop a portable, low-cost and real-time assaying platform that could 
potentially be used for on-site genetic testing. 
Advantages and Disadvantages of Genetic Testing 
The costs of different genetic tes ts vary depending on the test and lab 
being used but generally range trom $250 to $500.20 These tests may be 
covered by a pat1en!'s insurance plan, though many insurance compa-
nies consider them to be "investigational, experimental or unproven."6 
Due to evidence that genetic variations in the CYP2C19 gene are asso-
c1C1te<.J wiU1111creC1se<.J risks ror L11e occune11ce or adve1se ca1d10vasculC1r 
events and in-stent thromboses, using pharmacogenomics and genetic 
testing with clopidogrel therapy presents a real opportunity to decrease 
health care costs despite the added costs of the testing itself. The use 
of genetic tests can help the clinician identify and prevent situations in 
which patients undergo clopidogrel treatment 1hat is rendered ineffec-
tive due to their genetic makeup. However, these tests also may identify 
the need for a treatment that is likely to be more effective but also more 
costly. The clinical application of this technology also has some draw-
backs, including the invasive nature of these genetic tests, which require 
blood to be drawn. Moreover, including a genetic test before prescribing 
clopidogrel to a patient will increase turn-around time for a patient to 
receive ltle appropriate anti-platelet therapy. 
Using genetic tests to determine if a patient has any polymorph1Sms in 
the gene for CYP2C 19 may aid in individualizing and opt1m1zing clop1do-
grel treatment 12 In a study done at the Sinai Hospital in Baltimore, Md., 
those with the CYP2C 19'2 gene mutation demonstrated no difference 
in baseline platelet aggregation compared to those without the "loss 
of function" allele. 13 However, those with the mutation demonstrated 
greater residual platelet aggregation after clopidogrel therapy. After one 
year of follow-up, those with the CYP2C19'2 genotype had higher rates 
of cardiovascular events compared to those without the mutation. This 
demonstrates the advantages of using genetic testing in conj:mction with 
clopidogrel therapy. 
Conclusion 
Pharmac1Sts can play a key role in increasing awareness and acces-
s1b1hty of genetic testing, especially 1n the area of clopldogrel prescnbmg 
and dosing. It 1s the responsibility of pharmac1Sts to ensure that patients 
understand the benefits of these genetic tests In con.11mc11on with 
pharmacist-run anti-coagulation cl1n1cs, on-site genetlC testing and sub-
sequent clopidogrel dosing by a pharmacist could become a standard 
made available to patients. Pharmacists, in both community and hospital 
settings, may recommend to a prescriber an increased dose of clopido-
grel or a change in therapy to an entirely different med1cation for patients 
who have been deemed PMs according to results of their genetic test-
ing. Using data presented in the PRING trial, phanmacists can advocate 
for patients who are classified as PMs of clopdogrel, based on their 
genotype concerning the CYP2C19 gene, tote treated with higher load-
ing and maintenance doses. This will allow them to see platelet inhibition 
comparable to outcomes observed with the standard dosing in EMs. 
Such recommendations could consequently improve clinical outcomes 
for patients who would otherwise see no benefit from this pharmaceuti-
cal therapy; however, pa tients can only beneftt from ltlis type of interven-
llOn 1f their genotype can be quant1f1ed via genetic testing for vanants in 
the CYP2C19 gene. The application of these geneoc test results rs an 
area of practice that pharmacists can embrace as part of the movement 
toward increased patient counseling and medication therapy manage-
rnent. The use or genetic tes ting in tile prescription a11d dosing or 
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clopidogrel presents an opportunity for pharmacists in most practice set-
tings to expand the degree of care provided to patients by encouraging 
the personahzatlon of clopldogrel therapy. Rather than adhering to the 
current "one size fits air' method of prescribing, pharmacists have the 
opportunity to take a more proactive approach to customize antiplatelet 
therapy based on a pallent's mdiv1dual needs and significantly increase 
lfie elficacy or palient 11e1:1L111ent w1U1 clupic.Juyrel. 
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Assessment Questions 
1. Which of the following are utilized m genetic testing? 
a. AmpltCh1pr"' 
b. AccuType ™ 
c. VenfyNow-P2Y12 
d. A and 8 
2. AmpliChip™ uses __ to determine genotype. 
a. Probe drug 
b. PCR 
c. ADP agonist 
d. None of the above 
3. Which factor has been identified to contribute the most to variation in 
response to clopidogrel therapy? 
a. Variations m the CYP2C 19 enzyme 
b. Platelet receptor abnorm3lities 
c. Activity of GI esterases 
d. Activity of P-gp efflux pumps 
4. What 1s released from platelets during a normal response to tissue 
in Jury? 
a.PLC 
b. ATP 
c. ADP 
d. cAMP 
5. What percentage of a normal orally administered dose of clopidogrel 
is metabolized in the liver to the active form? 
a. 85 percent 
b. 50 percent 
c. 25 percent 
d. 15 percent 
6. An md!Vldual with two "toss of function" alleles 1s charactenzed as 
which type of metaboltzer? 
a. Extensive metabolizer 
b. Intermediate metabolizer 
c. Poor metabohzer 
d. Normal metabolizer 
7. According to the conclusions of the TRITON-TIMI study, all of the fol-
lowing are true for carriers of the CYP2C 19*2 variant EXCEPT: 
a. Decreased risk of in-stent thrombosis 
b. Increased risk of death from cardiovascular events 
c. Increased risk of non-fatal Ml or CVA 
d. Two of the above 
8. Which are ways that pharmacists can be involved in genetic testing 
and ctopldogre t dosing? 
a. Ensure that patients are aware of testing avallab1hty and 
benefits. 
b. Provide clinics or on-site genetic testing for patlents. 
c. Recommend a change in dosage or therapy if indicated by test 
re:; ult:;. 
d. All of the above 
9. According to the PRING study, which options are available to optimize 
therapy for poor metabolize rs of clopidogrel? 
a. Longer course of therapy 
b. Higher loading and maintenance doses 
c. Recommend switching to a different therapy 
d. Band C 
10. All of the following are benefits of genetic testing EXCEPT. 
a. Prevention of futile therapy 
b. Rapid time frame to achieving appropnate clopidogrel therapy 
c. Decreased overall health care costs 
d. Decreased clinical complicat10ns 
To receive continuing education credit for this program, you must 
answer the above questions and fill out the evaluation form. Please visit 
www.onu.edu/pharmacy--- to enter the required information. Please 
allow two to three weeks for electronic distribution of your continuing 
education certificate, which will be sent to your valid e-mail address in 
PDF format. 
Ohio Northern University is accredited bf the Accreditation 
Council for Pharmacy Educat10n as a provider of continuing 
pharmacy education. This program is eligitie for credit until 
Jan. 1B, 2014. 
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Office of Continuing Education at the Raabe College of Pha1macy 
Ohio Northem University 
525 South Main Street 
Ada, Ohio 45810 
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The program objectives were clear. 
The program met the stated goals & objectives; 
Describe the variables that account for differences in response to clopidogrel therapy 
and which accollllts for the most variation in response. 
List the clinical effects or complications that can result in a decreased patient response 
to clopidogrel. 
Explain the various testing methods available to detect a variation that can result in 
decreased clopidogrel response. 
Describe the various advantages and disadvantages to die testing mediods currendy available. 
Discuss what constitutes a poor metabolizer and what are the risks associated with this 
phenotype. 
Explain the pharmacist's role i11 advocating for and providing access to genetic testing. 
The program met your educational needs. 
Content of the program was interesting. 
Material presented was relevant to my practice. 
Comments/Suggestions for future programs: 
Thank Yon! 
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